AMSTERDAM (Reuters) - Mylan NV shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.

Shareholders also voted against a measure to approve the company's executive compensation. The shareholder campaign against Mylan's board picked up steam after Chairman Robert Coury's nearly $100 million pay package was disclosed earlier this year.

Coury made roughly $98 million in 2016, according to company filings, in a year in which the company faced criticism for the price of the emergency allergy device EpiPen and the stock fell almost 30%.

The generic pharmaceutical company came into the spotlight in August 2016 for raising the price of the EpiPen to $608.61 from $93.88 over the past decade. It caught the nation's attention because parents were refilling their kids' prescriptions, and some found that they were on the hook for hundreds of dollars for the device.

The company did not disclose the vote totals for the directors.

(Reuters reporting by Toby Sterling, Writing by Michael Erman in New York; Editing by Chizu Nomiyama)